Search
forLearn
5 / 801 resultslearn Tricopper peptides
learn Caprylic Triglyceride
learn copper tripeptide-1
learn PTT-6®
Research
5 / 62 results
research LH Induces Murine Hair Loss through TRPC-Medicated Cell Aging Responses: Implications for Female Pattern Hair Loss Pathogenesis
High LH levels cause hair loss by damaging and aging hair follicles.
research 1103 Derinat extends hair cycle at anagen phase by decreasing the level of TRPCs-mediated intracellular ROS accumulation in skin
Derinat helps extend hair growth by reducing harmful molecules in skin cells.
research Store-operated calcium channels in skin
Calcium channels are vital for normal skin function and their dysfunction can lead to skin issues.
research Transient Ca2+ entry by plasmalogen-mediated activation of receptor potential cation channel promotes AMPK activity
Plasmalogens activate a channel in cells that may stimulate hair growth.
research A New Role of Non-Sex Hormone in the Pathogenesis of Female Pattern Hair Loss
Elevated luteinizing hormone contributes to female-pattern hair loss, and blocking certain channels may help prevent it.
Community Join
5 / 1000+ resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Proof DHT is not the main cause of hair loss. TRPS1 Gene and Protein might be. PP405 won’t work. AMP-303 might!
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community TRT. Pyrilutamide. Ru58841. Help
A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.